Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · IEX Real-Time Price · USD
5.92
-0.15 (-2.47%)
Mar 28, 2024, 9:57 AM EDT - Market open

Aprea Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017
Revenue
0.58000000
Gross Profit
0.58000000
Selling, General & Admin
8.4320.9713.5514.938.592.292.46
Research & Development
7.6316.423.937.8820.9514.1913.39
Other Operating Expenses
076.0200000
Operating Expenses
16.06113.3937.4552.8129.5416.4915.85
Operating Income
-15.47-113.39-37.45-52.81-29.54-16.49-15.85
Interest Expense / Income
-1.22-0.45-0-0.22-0.1600
Other Expense / Income
0.04-0.28-0.320.89-1.33-0.96-0.66
Pretax Income
-14.29-112.66-37.13-53.48-28.06-15.53-15.19
Net Income
-14.29-112.66-37.13-53.48-28.06-15.53-15.19
Shares Outstanding (Basic)
4211000
Shares Outstanding (Diluted)
4211000
Shares Change
118.32%55.69%0.72%252.08%419.98%0.11%-
EPS (Basic)
-3.95-67.99-34.88-50.61-93.40-269.00-263.40
EPS (Diluted)
-3.95-67.99-34.88-50.61-93.40-269.00-263.40
Free Cash Flow
-12.27-25.01-37.69-41.83-26.74-15.25-14
Free Cash Flow Per Share
-3.39-15.09-35.41-39.59-89.09-264.28-242.87
Gross Margin
100.00%------
Operating Margin
-2652.80%------
Profit Margin
-2449.59%------
Free Cash Flow Margin
-2103.92%------
EBITDA
-15.5-112.92-36.86-53.47-28.05-15.52-15.18
EBITDA Margin
-2658.27%------
Depreciation & Amortization
0.010.190.270.230.170.010.01
EBIT
-15.51-113.11-37.13-53.7-28.22-15.53-15.19
EBIT Margin
-2659.48%------
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).